Arteriosclerosis and Thrombosis, Vol 12, 19-27, Copyright © 1992 by American Heart Association

ARTICLES

Hypertriglyceridemia and regulation of fibrinolytic activity

L Mussoni, L Mannucci, M Sirtori, M Camera, P Maderna, L Sironi and E Tremoli
E. Grossi Paoletti Center, University of Milan, Italy.

A relation between elevated triglyceride (TG) levels and alterations of the fibrinolytic system has been recognized in studies of patients with coronary heart disease. In this investigation, the total fibrinolytic activity and the levels of specific components of the fibrinolytic system were evaluated in plasma samples from a highly selected group of patients with type IV hyperlipoproteinemia before and after a dietary treatment aimed at reducing TG levels. The fibrinolytic response of type IV patients was comparable to that of normolipidemic subjects, whereas tissue-type plasminogen activator antigen levels before and after venous occlusion (p less than 0.01) and resting plasminogen activator inhibitor-1 (PAI-1) antigen (p less than 0.01) and activity (p less than 0.01) were significantly higher in hypertriglyceridemic subjects compared with controls. After dietary treatment, a 22% reduction in TG levels was attained in type IV patients, with no appreciable modification of fibrinolytic parameters. The analysis of the single-patient data revealed a tendency toward normalization of PAI- 1 levels only in those patients who showed a TG reduction greater than or equal to 20%. Very low density lipoproteins (VLDLs) from both normal and type IV patients concentration-dependently stimulated PAI-1 release by endothelial cells and HepG2 cells, with the effect of VLDL from type IV patients being more pronounced on HepG2 cells. The release of PAI-1 induced by VLDL in competent cells may thus account for the elevated levels of this antifibrinolytic protein that occur in hypertriglyceridemic patients.

This article has been cited by other articles:

				C. J. Lyon, R. E. Law, and W. A. Hsueh Minireview: Adiposity, Inflammation, and Atherogenesis Endocrinology, June 1, 2003; 144(6): 2195 - 2200. [Abstract] [Full Text] [PDF]

				T. Tholstrup, G. J Miller, A. Bysted, and B. Sandstrom Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men Am. J. Clinical Nutrition, May 1, 2003; 77(5): 1125 - 1132. [Abstract] [Full Text] [PDF]

				S. B. Dent, C. T. Peterson, L. D. Brace, J. H. Swain, M. B. Reddy, K. B. Hanson, J. G. Robinson, and D. L. Alekel Soy Protein Intake by Perimenopausal Women Does Not Affect Circulating Lipids and Lipoproteins or Coagulation and Fibrinolytic Factors J. Nutr., September 1, 2001; 131(9): 2280 - 2287. [Abstract] [Full Text] [PDF]

				E. M. Tabengwa, R. L. Benza, H. E. Grenett, and F. M. Booyse Hypertriglyceridemic VLDL Downregulates Tissue Plasminogen Activator Gene Transcription Through cis-Repressive Region(s) in the Tissue Plasminogen Activator Promoter in Cultured Human Endothelial Cells Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1675 - 1681. [Abstract] [Full Text] [PDF]

				W. Dichtl, A. Stiko, P. Eriksson, I. Goncalves, F. Calara, C. Banfi, M. P. S. Ares, A. Hamsten, and J. Nilsson Oxidized LDL and Lysophosphatidylcholine Stimulate Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 3025 - 3032. [Abstract] [Full Text] [PDF]

				C. Banfi, L. Mussoni, P. Rise, M. G. Cattaneo, L. Vicentini, F. Battaini, C. Galli, and E. Tremoli Very Low Density Lipoprotein–Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells Circ. Res., July 23, 1999; 85(2): 208 - 217. [Abstract] [Full Text] [PDF]

				M. A. van den Dorpel, A. J. M. i.'t Veld, M. Levi, J. W. ten Cate, and W. Weimar Beneficial Effects of Conversion From Cyclosporine to Azathioprine on Fibrinolysis in Renal Transplant Recipients Arterioscler Thromb Vasc Biol, June 1, 1999; 19(6): 1555 - 1558. [Abstract] [Full Text] [PDF]

				L. Nilsson, T. Takemura, P. Eriksson, and A. Hamsten Effects of Fibrate Compounds on Expression of Plasminogen Activator Inhibitor-1 by Cultured Endothelial Cells Arterioscler Thromb Vasc Biol, June 1, 1999; 19(6): 1577 - 1581. [Abstract] [Full Text] [PDF]

				L. Nilsson, M. Gåfvels, L. Musakka, K. Ensler, D. K. Strickland, B. Angelin, A. Hamsten, and P. Eriksson VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor J. Lipid Res., May 1, 1999; 40(5): 913 - 919. [Abstract] [Full Text]

				B. A. Allison, L. Nilsson, F. Karpe, A. Hamsten, and P. Eriksson Effects of Native, Triglyceride-Enriched, and Oxidatively Modified LDL on Plasminogen Activator Inhibitor-1 Expression in Human Endothelial Cells Arterioscler Thromb Vasc Biol, May 1, 1999; 19(5): 1354 - 1360. [Abstract] [Full Text] [PDF]

				A. Festa, R. D'Agostino Jr, L. Mykkanen, R. Tracy, B. V. Howard, and S. M. Haffner Low-Density Lipoprotein Particle Size Is Inversely Related to Plasminogen Activator Inhibitor-1 Levels : The Insulin Resistance Atherosclerosis Study Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 605 - 610. [Abstract] [Full Text] [PDF]

				R. L. Benza, H. E. Grenett, R. C. Bourge, J. K. Kirklin, D. C. Naftel, P. F. Castro, D. C. McGiffin, J. F. George, and F. M. Booyse Gene Polymorphisms for Plasminogen Activator Inhibitor-1/Tissue Plasminogen Activator and Development of Allograft Coronary Artery Disease Circulation, November 24, 1998; 98(21): 2248 - 2254. [Abstract] [Full Text] [PDF]

				L. Nilsson, C. Banfi, U. Diczfalusy, E. Tremoli, A. Hamsten, and P. Eriksson Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1679 - 1685. [Abstract] [Full Text] [PDF]

				M. P. Moyer, R. P. Tracy, P. B. Tracy, C. v.'t Veer, C. E. Sparks, and K. G. Mann Plasma Lipoproteins Support Prothrombinase and Other Procoagulant Enzymatic Complexes Arterioscler Thromb Vasc Biol, March 1, 1998; 18(3): 458 - 465. [Abstract] [Full Text] [PDF]

				L. Byberg, A. Siegbahn, L. Berglund, P. McKeigue, R. Reneland, and H. Lithell Plasminogen Activator Inhibitor-1 Activity Is Independently Related to Both Insulin Sensitivity and Serum Triglycerides in 70-Year-Old Men Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 258 - 264. [Abstract] [Full Text] [PDF]

				P. Eriksson, L. Nilsson, F. Karpe, and A. Hamsten Very-Low-Density Lipoprotein Response Element in the Promoter Region of the Human Plasminogen Activator Inhibitor-1 Gene Implicated in the Impaired Fibrinolysis of Hypertriglyceridemia Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 20 - 26. [Abstract] [Full Text] [PDF]

				J. Arts, M. Kockx, H. M.G. Princen, and T. Kooistra Studies on the Mechanism of Fibrate-Inhibited Expression of Plasminogen Activator Inhibitor-1 in Cultured Hepatocytes From Cynomolgus Monkey Arterioscler Thromb Vasc Biol, January 1, 1997; 17(1): 26 - 32. [Abstract] [Full Text]

				A. Broijersen, M. Eriksson, B. Wiman, B. Angelin, and P. Hjemdahl Gemfibrozil Treatment of Combined Hyperlipoproteinemia : No Improvement of Fibrinolysis Despite Marked Reduction of Plasma Triglyceride Levels Arterioscler Thromb Vasc Biol, April 1, 1996; 16(4): 511 - 516. [Abstract] [Full Text]

				M. Cigolini, G. Targher, I.A. B. Andreis, M. Tonoli, G. Agostino, and G. De Sandre Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy Men Arterioscler Thromb Vasc Biol, March 1, 1996; 16(3): 368 - 374. [Abstract] [Full Text]

				Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy BMJ, February 24, 1996; 312(7029): 473 - 478. [Abstract] [Full Text]

				L. Sironi, L. Mussoni, L. Prati, D. Baldassarre, M. Camera, C. Banfi, and E. Tremoli Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 89 - 96. [Abstract] [Full Text]

				L. Tenkanen, M. Manttari, and V. Manninen Some Coronary Risk Factors Related to the Insulin Resistance Syndrome and Treatment With Gemfibrozil : Experience From the Helsinki Heart Study Circulation, October 1, 1995; 92(7): 1779 - 1785. [Abstract] [Full Text]

				O. Vaarala, M. Manttari, V. Manninen, L. Tenkanen, M. Puurunen, K. Aho, and T. Palosuo Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men Circulation, January 1, 1995; 91(1): 23 - 27. [Abstract] [Full Text]